The CBIS Global Consortium provides the us with a framework to cooperate and collaborate with...
There are no announcements yet.
The objective of the consortium is to harness the collective expertise of our global partners to investigate the use of Cannabinoids for the treatment of a variety of indications, including cancers, neurological conditions, pain management, the treatment of HIV and AIDS, and epilepsy.
The Cannabis Science Global Consortium will link universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside. The CBIS Global Consortium will also enable the Company to more strategically coordinate its initiatives, including those focused on education, job creation, and skills training.
There are three primary elements in Cannabis Science's drug development program:
Defining the effectiveness and specificity of cannabinoids being tested;
Identifying and testing drug delivery mechanisms; and
Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in our randomized controlled trials. The Company's initial results point to the importance of drug delivery systems and the impact of co-interventions
STC is regulated by the Securities and Exchange Commission
2901 N Dallas Parkway
Suite 380
Plano, Texas 75093
(469) 633-0101
FINAL Updated CSi – First Rights DATES !!!
*** March 31, 2021 is the Last Day for the CSi First Rights offering.
We need to begin the Cannabis...FINAL Updated CSi – First Rights DATES !!!
*** March 31, 2021 is the Last Day for the CSi First Rights offering.
We need to begin the Cannabis Science CSi share exchange with Omnicanna, so this is it.
As promised, we are reaching out to every email from every shareholder responding to the CSi- FR opportunity, Thanks for your patience. This extra time will allow us to do so. This will be the last extension as we need to begin the Cannabis Science share exchange and issue the first batch of the CSi – First Rights shares in ENDO immediately.
*** As planned, beginning March 1, 2021, we are now completing the paperwork and beginning to issue the first batch of CSi-First Rights ENDO shares right now.
If you have not already sent in your paperwork, please do now to be a part of this first group of share issuances. Otherwise, all the Best, we expect your Cannabis Science shares to do very well, as well !!!
We are booked solid though to mid-March at this point, if you book a call you will be included, so just book something before the end of March 2021 and you will be included.
We will announce the next update on this matter as we begin to issue this first batch of CSi-FR ENDO shares and make announcements for the first batch of CSi – ENDO share exchange shares right behind it.
Cheers!
Stay Safe and Strong.
Talk soon.
Raymond
Show more